Factor VIII immunogenicity

Haemophilia

Volumn 4, Issue 4, 1998, Pages 552-557

  Jacquemin, M G ^a   Saint Remy, J M R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

B cell; Haemophilia; Inhibitors; T cell; Tolerance

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8;

CONFERENCE PAPER; DISEASE SEVERITY; HEMOPHILIA A; HOST SUSCEPTIBILITY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL;

EID: 0031876991     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440552.x     Document Type: Conference Paper

References (38)

1. Cerottini JC, MacDonald HR. The cellular basis of T cell memory. Ann Rev Immunol 1989; 7: 77-89.
2. Klinman NR. The "clonal selection hypothesis" and current concepts of B cell tolerance. Immunity 1996; 5: 189-95.
3. Nossal GJV. Negative selection of lymphocytes. Cell 1994; 76: 229-39.
4. Gilles JGG, Saint-Remy JMR. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-1505.
5. Algiman M, Dietrich G, Nydegger U, Boiledieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992; 89: 3795-9.
6. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995; 7: 812-8.
7. Cook MC, Basten A, Fazekas de St. Groth B. Outer periarteriolar lymphoid sheath arrest and subsequent differentiation of both naive and tolerant immunoglobulin transgenic B cells is determined by B cell receptor occupancy. J Exp Med 1997; 186: 631-43.
8. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to Factor VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74: 311-6.
9. Adelstein S, Pritchard-Briscoe H, Anderson TA, Crosbie J, Gammon G, Loblay RH, et al. Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen, Science 1991; 251: 1223-5.
10. Jerne NK. Idiotype networks and other preconceived ideas. Immunol Rev 1984; 79: 5-24.
11. Singer ST, Addiego JE, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
12. Gilles JG, Saint-Remy JMR. Coagulation Factor VIII autoantibodies. In: Autoantibodies, Peter JB, Shoenfeld Y, eds. Amsterdam: Elsevier, 1996; 172-8.
13. Fulcher CA, Mahoney S, Zimmerman TS. Factor VIII inhibitor subclass and factor VIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
14. Gilles JG, Jacquemin M, Saint-Remy JMR. Factor VIII inhibitors. Thromb Haemost 1997; 78: 641-6.
15. Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, et al. Molecular characterisation of a factor VIII specific IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1997; 90(suppl 1): 463a.
16. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JMR. Anti-Factor VIII antibodies of haemophiliac patients are directed primarily towards non-functional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
17. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JMR. Neutralising anti-idiotypic antibodies to factor VIII inhibitors following desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
18. Gilles JGG, Arnout J, Peerlinck K, Vermylen J, Saint-Remy JMR. Antigen-antibody complexes made of FVIII and autologous specific antibodies down-regulate the production of anti-Factor VIII antibodies. Abstract 85. 21st International Congress of the World Federation of Hemophilia, Mexico City, Mexico, 1994.
19. Saint-Remy JMR, Jacquemin M, Gilles JG. Anti-idiotypic antibodies: from regulation to therapy of factor VIII inhibitors. Vox Sanguinis, in press.
20. Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cells response. J Immunol 1994; 152: 1453-61.
21. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995; 74: 619-21.
22. Thompson AR, Murphy EP, Liu ML, Saenko EL, Healey JF, Lollar P, Scandella D. Loss of tolerance to exogeneous and endogeneous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood 1997; 90: 1902-10.
23. 22b Peerlinck K, Arnout J, Jacquemin MG, Gilles JG, Lavend'homme R, Kreson K, et al. A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management and partial characterization of the inhibitor. Blood 1997; 90 (Suppl 1): 36a.
24. Fijnvandraat K, Turenhout EAM, van denBrink EN, ten Cate JW, van Mourik JA, Peters M, Voorberg J. The missense mutation Arg593 to Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997; 89: 4371-7.
25. Johnson JG, Jemmerson R. Tolerance induction in resting memory B cells specific for a protein antigen. J Immunol 1992; 148: 2682-9.
26. Shokat KM, Goodnow CC. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 1995; 375: 334-8.
27. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia a patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
28. Peerlinck K, Arnout J, diGiambattista M, Gilles JG, Laub R, Jacquemin M, et al. Factor VIII inhibitors in previously treated hemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
29. Rosendaal FR. Factor VIII inhibitors on a SD-treated and pasteurised concentrate associated with specific batches and batch characteristics. Thromb Haemost 1997; 77 (Suppl 1): 590.
30. Laub R, diGiambattista M, Fondu P, Brackmann HH, Lenk H, Scandella D. Restricted epitope specificity of factor VIII inhibitors which appeared in previously treated hemophiliacs after infusion with Octavi SD Plus. Thromb Haemost 1997; 77 (Suppl 1): 590.
31. Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976; 116: 1-7.
32. Ginsburg D, Roberts HR, High KA. Hemophilia and von Willebrand disease. In: Hematology 1997, Education Program, 39th Annual Meeting, American Society of Hematology, December 1997, San Diego, pp 29-45.
33. Gilles JG, Saint-Remy JMR. Recombinant and plasma-derived facor VIII are immunologically distinct in vitro assays. Thromb Haemost 1995; 73: 1213.
34. Lusher JM, Spira J, the ReFacto PUP study group. Safety, efficacy and inhibitor development in previously untreated patients treated exclusively with recombinant B-domain deleted FVIII (rVIII-SQ): 2.5 study years. Blood 1997; 90 (Suppl 1): 599a.
35. Wadhwa M, Dilger P, Tubbs J, Miresluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: A possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84: 2021-30.
36. Hanahan D. Transgenic mouse models of self-tolerance and autoreactivity by the immune system. Ann Rev Cell Biol 1990; 6: 493-537.
37. Saint-Remy JMR, Gilles JG. Variations in antigenicity of factor VIII concentrates: preclinical evaluation. Vox Sang 1996; 70 (Suppl 1): 15-8.
38. Vanzieleghem B, Gilles JG, Vermylen J, Saint-Remy JMR. In vivo production of functional anti-factor VIII antibodies in severe combined immunodeficiency (SCID) mice reconstituted with PBL of healthy blood donors. Thromb Haemost 1997; 77 (Suppl 1): 590.